- Home
- TRAK vs RGNX Comparison
TRAK vs RGNX Comparison
Compare TRAK & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRAK
- RGNX
- Stock Information
- Founded
- TRAK 1990
- RGNX 2008
- Country
- TRAK United States
- RGNX United States
- Employees
- TRAK N/A
- RGNX N/A
- Industry
- TRAK EDP Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRAK Technology
- RGNX Health Care
- Exchange
- TRAK Nasdaq
- RGNX Nasdaq
- Market Cap
- TRAK 366.3M
- RGNX 387.0M
- IPO Year
- TRAK 1998
- RGNX 2015
- Fundamental
- Price
- TRAK $20.11
- RGNX $7.82
- Analyst Decision
- TRAK Strong Buy
- RGNX Strong Buy
- Analyst Count
- TRAK 1
- RGNX 8
- Target Price
- TRAK $24.00
- RGNX $31.75
- AVG Volume (30 Days)
- TRAK 57.1K
- RGNX 1.0M
- Earning Date
- TRAK 05-14-2025
- RGNX 05-07-2025
- Dividend Yield
- TRAK 0.36%
- RGNX N/A
- EPS Growth
- TRAK 14.28
- RGNX N/A
- EPS
- TRAK 0.32
- RGNX N/A
- Revenue
- TRAK $21,199,507.00
- RGNX $83,328,000.00
- Revenue This Year
- TRAK $15.61
- RGNX $285.14
- Revenue Next Year
- TRAK $15.00
- RGNX N/A
- P/E Ratio
- TRAK $62.99
- RGNX N/A
- Revenue Growth
- TRAK 6.99
- RGNX N/A
- 52 Week Low
- TRAK $14.23
- RGNX $5.04
- 52 Week High
- TRAK $25.01
- RGNX $17.99
- Technical
- Relative Strength Index (RSI)
- TRAK 53.05
- RGNX 59.58
- Support Level
- TRAK $19.68
- RGNX $5.85
- Resistance Level
- TRAK $20.36
- RGNX $6.83
- Average True Range (ATR)
- TRAK 1.03
- RGNX 0.68
- MACD
- TRAK 0.11
- RGNX 0.11
- Stochastic Oscillator
- TRAK 94.21
- RGNX 99.64
About TRAK ReposiTrak Inc.
ReposiTrak Inc is a software as a service provider with extensive capabilities that gives their customers an easy, cost-efficient way to expand their services to their benefit. The company and its subsidiaries develop, market, and support proprietary software products. These products assist the management of business operations, which helps clients to make more informed decisions. The company also provides a cloud-based solution to remain in compliance with business records and regulatory requirements. The firm's services comprise implementation, business optimization, outsourcing, technical services, education, and application hosting.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.